Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

CryoPort, Inc. - Common Stock (NQ:CYRX)

7.560 -0.090 (-1.18%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 29, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about CryoPort, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
12 Health Care Stocks Moving In Thursday's Pre-Market Session
 
Via Benzinga
Why Is CryoPort (CYRX) Stock Down 26% Today?
CryoPort (CYRX) stock is falling on Thursday after the cell and gene therapy products company released preliminary results for Q2 2023. 
Via InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
We're starting off Thursday with a look at the biggest pre-market stock movers traders will want to keep an eye on this morning. 
Via InvestorPlace
12 Health Care Stocks Moving In Wednesday's After-Market Session
 
Via Benzinga
Looking Into CryoPort's Return On Invested Capital
 
Via Benzinga
CryoPort: Q1 Earnings Insights
 
Via Benzinga
Expert Ratings for CryoPort
 
Via Benzinga
5 Analysts Have This to Say About CryoPort
 
Via Benzinga
What 5 Analyst Ratings Have To Say About CryoPort
 
Via Benzinga
Something Happened In Biotech Last Week
Biotech stocks were more constructive last week with some sharp moves up. 
Via Talk Markets
Cryoport Supports Clinical Trials And Commercial Therapies Across The High-Growth BioTech Industry: Is Its Current Stock Price An Opportunity?
The global biotechnology industry was worth $859 billion in 2022, and it is predicted to reach $1.6 trillion by 2030, growing at a compound annual growth rate (CAGR) of 8.7% over the forecast period.  
Via Benzinga
Cryoport: Temperature-Controlled Supply Chain Solutions Provider Sees Almost 30% Bump In Revenues
Robert Stefanovich, CFO of Cryoport, Inc. (NASDAQ: CYRX), was recently a guest on Benzinga’s All-Access. 
Via Benzinga
Cell Therapy Has Shown Near Miraculous Remission Rates In Cancer Patients, But The Growing Industry Relies On This Company – A Uniquely Positioned Ticker In The Weeds?
Cell Therapy Has Shown Near Miraculous Remission Rates In Cancer Patients, But The Growing Industry Relies On This Company – A Uniquely Positioned Ticker In The Weeds? 
Via News Direct
Topics Economy
Expert Ratings for CryoPort
 
Via Benzinga
What 4 Analyst Ratings Have To Say About CryoPort
 
Via Benzinga
Cell Therapy Has Shown Near Miraculous Remission Rates In Cancer Patients, But The Growing Industry Relies On This Company – A Uniquely Positioned Ticker In The Weeds?
By David Willey, Benzinga 
Via TheNewswire.com
Topics Economy
Cell Therapy Has Shown Near Miraculous Remission Rates In Cancer Patients, But The Growing Industry Relies On This Company – A Uniquely Positioned Ticker In The Weeds?
Cryoport Inc. (NASDAQ: CYRX) provides the life sciences industry with comprehensive supply chain solutions to support vital therapeutics. 
Via Benzinga
Stocks Extend Slump, Head For Weekly Losses
Stocks are extending their premarket losses, with the Dow Jones Industrial Average down 409 points. 
Via Talk Markets
Kratos Defense & Security, Zeta Global, Beacon Roofing Supply And Other Big Stocks Moving Higher On Friday
U.S. stocks traded lower, with the Dow Jones dropping more than 400 points on Friday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Toll Brothers To Rally 25%? Here Are 10 Other Analyst Forecasts For Friday
Oppenheimer boosted the price target for Universal Display Corporation (NASDAQ: OLED) from $150 to $160. Oppenheimer analyst Martin Yang maintained an Outperform rating on the stock. Universal Display... 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
 
Via Benzinga
When Small Cap Biotechs Lose Momentum: Are You An Investor Or A Trader?
A few small cap biotechs lost momentum last week so now might be the time to take profits. But many of these stocks are favored because of their core technology and favored by funds; time to buy? 
Via Talk Markets
Amazon, Apple, Tesla And Other Big Gainers From Thursday
U.S. stocks closed higher on Thursday, with the Dow Jones jumping more than 1,200 points. Here is the list of some big stocks recording gains in the previous session. 
Via Benzinga
Why Apyx Medical Shares Dipped Over 60%; Here Are 123 Biggest Movers From Yesterday
Gainers 
Via Benzinga
Yelp, Twilio, Atlassian, And Other Big Losers From Friday
U.S. stocks closed higher on Friday, with the Dow Jones surging more than 400 points. Here is the list of some big stocks recording losses in the previous session. 
Via Benzinga
Why Yelp Shares Are Trading Lower By 15%? Here Are 86 Stocks Moving In Friday's Mid-Day Session
Gainers 
Via Benzinga
Why MediaAlpha Shares Jumped Around 30%; Here Are 112 Biggest Movers From Friday
Gainers 
Via Benzinga
Whither Small Caps After Fed’s Tough Talk?
For now its better not to “Fight the Fed” because they are fighting the with the market. Now that everyone is scared of the Fed's rhetoric it would be better to wait a week or so as more data and... 
Via Talk Markets
CryoPort Earnings Perspective: Return On Capital Employed
According to Benzinga Pro data, during Q2, CryoPort (NASDAQ:CYRX) posted sales of $64.15 million. Earnings were up 31.54%, but CryoPort still reported an overall loss of $9.18 million. 
Via Benzinga
Check your Portfolio for Small Cap Weighting: Growth, Innovation or Speculation?
The SPDR S&P Biotech ETF remains our key indicator for small cap biotechs. It is up 14.55% over one month at $93.78 but is still down 16% YTD. The Russell 2000 is up 16.5% over one month mirroring... 
Via Talk Markets
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.